Clinical Trial of HY004 Cell Injection in the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
Study Details
Study Description
Brief Summary
This is a multi-center, open-label, single-arm, phase I/II trial to evaluate the safety and efficacy of HY004 treatment in Adult patients with relapsed or refractory B-cell Non-Hodgkin's Lymphoma (r/r B-NHL).
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1/Phase 2 |
Detailed Description
This trial is a multi-center, open label, single-arm, phase I/II trial to evaluate the safety and efficacy of HY004 in Adult(aged 18~75 years old) patients with r/r B-NHL.
The phase I part of the trial is to evaluate the safety, optimal dose of HY004, Pharmacokinetics/Pharmacodynamics(PK/PD)and preliminary efficacy in the treatment of Adult patients with r/r B-NHL. The phase II part of the trial is to evaluate the efficacy and safety of HY004 in in the treatment of Adult patients with r/r B-NHL. The study includes screening, pre-treatment (Cell Product manufacture & lymphodepletion), HY004 infusion , safety and efficacy follow-up, and survival follow-up. All subjects who have received HY004 infusion will be followed for up to 2 years.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Single dose of HY004 Patients received a single dose of anti-CD22/CD19 CAR T cells after receiving a conditioning regimen of cyclophosphamide and fludarabine. |
Biological: HY004
Autologous 2nd generation bispecific CAR-T cells targeting both CD22 and CD19, single infusion intravenously.
Start Dose level: 2.00 x 10^6/kg CAR+T-cells
|
Outcome Measures
Primary Outcome Measures
- 【Phase I】Maximum Tolerated Dose (MTD), Dose Limiting Toxicity (DLT) and Recommended Phase II Dose (RP2D) [28 days]
Determine the MTD and DLT of HY004 in the Treatment and recommend the dose for Phase II study.
- 【Phase II】Overall Remission Rate (ORR), which includes Complete Remission (CR) and Partial Remission (PR) [3 months]
Efficacy of HY004 as measured by ORR at 3 months after HY004 Cell Injection infusion, which includes CR and PR.
Secondary Outcome Measures
- 【Phase I】Overall Remission Rate (ORR), which includes Complete Remission (CR) and Partial Remission (PR) [3 months]
Efficacy of HY004 as measured by ORR at 3 months after HY004 Cell Injection infusion, which includes CR and PR.
- Safety of CNCT19 therapy: CTCAE v5.0 [24 months]
Safety measures include adverse events as assessed by CTCAE v5.0.
- Complete Remission Rate (CRR) [3 months]
Efficacy of HY004 as measured by CR at 3 months after HY004 Cell Injection infusion.
- ORR（CR+PR）/CRR [28 days]
Efficacy of HY004 as measured by ORR/CRR at 28 days after cell infusion.
- ORR（CR+PR）/CRR [6 months]
Efficacy of HY004 as measured by ORR/CRR at 6 months after cell infusion.
- Best Overall Response (BOR) [24 mouths]
The best overall response after HY004 infusion.
- Duration of Remission (DOR) [24 mouths]
DOR means the duration from reaching the response (e.g., CR or PR) criteria of the therapy to the first, clearly defined progressive disease, or death for disease under investigation.
- Progression-free survival (PFS) [24 mouths]
PFS means duration from the HY004 Cell Injection infusion to progression of lymphoma, or death for any reason.
- Event-free survival (EFS) [24 mouths]
EFS means duration from the HY004 Cell Injection infusion to progression of lymphoma, start of new anti-cancer treatment, relapse, death of any cause or discontinued due to any adverse events.
- Overall survival (OS) [24 mouths]
OS is defined as the time from the signing of informed consent form to the date of the last survival follow-up or death due to any cause.
Other Outcome Measures
- In vivo cellular Pharmacokinetic (PK) profile of HY004. [24 mouths]
To characterize the in vivo cellular pharmacokinetic (PK) profile (levels, persistence, trafficking) of HY004 cells in blood by quantitative polymerase chain reaction(qPCR) and Flow Cytometry.
- In vivo cellular pharmacodynamics (PD) profile of HY004. [3 mouths]
To characterize the concentration of cytokines ,including Interleukin-6(IL-6) at least in Serum.
- Prevalence and incidence of humoral immunogenicity to HY004. [24 mouths]
To characterize the concentration of anti-drug antibodies
Eligibility Criteria
Criteria
Key Inclusion Criteria:
-
Patients who are willing to sign the informed consent form;
-
Aged 18-75 years, male or female;
-
Previously received≥2nd-line adequate therapy or hematopoietic stem cell transplantation (HSCT), and patients with CD19+/CD22+ relapsed/refractory B-NHL according to the WHO classification 2017, which are provided specifically as follows:
-
Diffuse large B cell lymphoma (DLBCL), not otherwise specified (NOS);
-
Primary mediastinal large B cell lymphoma (PMBCL);
-
Grade 3b follicular lymphoma;
-
Transformed follicular lymphoma;
-
High grade B cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements, and high grade B cell lymphoma - not otherwise specified.
-
Measurable imaging lesion at screening: Intranodal lesion must have a long diameter of more than 1.5 cm, and extranodal lesion must have a long diameter of more than 1.0 cm with PET-positive disease by Lugano classification .
-
PET-positive disease BY Lugano classification
-
Adequate bone marrow, renal, hepatic, pulmonary and cardiac function.
-
Adequate vascular access for leukapheresis procedure
-
Subjects who have received previous CD19-targeted therapy must have CD19-positive lymphoma confirmed on a biopsy since completing the prior CD19-targeted therapy.
Key Exclusion Criteria:
-
Active Central Nervous System (CNS) involvement by malignancy.
-
Patients with existing central nervous system disease or with a history of central nervous system disease.
-
Patients receiving any of the following drugs or therapies within the specified period prior to apheresis:
-
Alemtuzumab and Bendamustine within 6 months prior to apheresis;
-
Cladribine within 3 months prior to apheresis;
-
Lenalidomide within 1 mouth prior to apheresis;
-
Lymphocytotoxic chemotherapy within 2 weeks prior to apheresis - use in more than 3 half-lives prior to apheresis is eligible;
-
Anti-CD20 monoclonal antibody and therapeutic dose of hormones within 7 d prior to apheresis;
-
Non-lymphocytotoxic chemotherapy within 7 d prior to apheresis - use in more than 3 half-lives prior to apheresis is eligible;
-
Venetoclax (BCL-2 inhibitor) within 4 d prior to apheresis;
-
Idelalisib (PI3Kδ kinase inhibitor) within 2 d prior to apheresis;
-
DLI within 6 weeks prior to apheresis;
-
Radiotherapy within 6 weeks prior to apheresis - progressive disease at radiotherapy site, or PET positive lesion at other non-radiotherapy site is eligible;
-
Patients previously received CAR-T cell therapy, the products that have same indication and have beenlisted in China are eligible;
-
Patients who have previously received allogeneic hematopoietic stem cell transplantation (allo-HSCT) within 3 mouths.
-
Patients with acute graft-versus-host disease (GVHD) or moderate-tosevere chronic GVHD within 4 weeks before screening.
-
Active systemic autoimmune disease.
-
Known infection with human immunodeficiency virus (HIV) or chronic infection with hepatitis B virus (HbsAg positive) or hepatitis C virus (anti- HCV positive).
-
Patients with active infections at screening.
-
History of cardiovascular disease.
-
Pregnant or nursing women.
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Juventas Cell Therapy Ltd.
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- HY004102